Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 256-261

  Magis Escurra, C ^a   Alffenaar, J W ^b   Hoefnagels, I ^c   Dekhuijzen, P N R ^a   Boeree, M J ^a   Van Ingen, J ^a   Aarnoutse, R E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clarithromycin; Interaction; NTM disease; Pharmacokinetics; Rifampicin

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; HUMAN; LUNG INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION;

CLARITHROMYCIN; INTERACTION; NTM DISEASE; PHARMACOKINETICS; RIFAMPICIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTITUBERCULAR; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84883454533     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.05.007     Document Type: Article

References (26)

1. C.L. Daley, and D.E. Griffith Pulmonary non-tuberculous mycobacterial infections Int J Tuberc Lung Dis 14 2010 665 671
2. D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanzaro, C. Daley, and F. Gordin An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 2007 367 416
3. J. van Ingen, S.A. Bendien, W.C. de Lange, W. Hoefsloot, P.N. Dekhuijzen, and M.J. Boeree Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands Thorax 64 2009 502 506
4. J. van Ingen, W. Hoefsloot, P.N. Dekhuijzen, M.J. Boeree, and D. van Soolingen The changing pattern of clinical Mycobacterium avium isolation in The Netherlands Int J Tuberc Lung Dis 14 2010 1176 1180
5. P.K. Lam, D.E. Griffith, T.R. Aksamit, S.J. Ruoss, S.M. Garay, and C.L. Daley Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease Am J Respir Crit Care Med 173 2006 1283 1289
6. E.E. McGrath, and P.B. Anderson The therapeutic approach to non-tuberculous mycobacterial infection of the lung Pulm Pharmacol Ther 23 2010 389 396
7. R.J. Wallace Jr., B.A. Brown, D.E. Griffith, W. Girard, and K. Tanaka Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection J Infect Dis 171 1995 747 750
8. C.A. Peloquin, and S.E. Berning Evaluation of the drug interaction between clarithromycin and rifampin J Infect Dis Pharmacother 2 1996 19 35
9. J.W. Alffenaar, W.A. Nienhuis, F. de Velde, A.T. Zuur, A.M. Wessels, and D. Almeida Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection Antimicrob Agents Chemother 54 2010 3878 3883
10. J. van Ingen, E.F. Egelund, A. Levin, S.E. Totten, M.J. Boeree, and J.W. Mouton The pharmacokinetics of pulmonary Mycobacterium avium complex disease treatment and its relation to drug susceptibility testing results Am J Respir Crit Care Med 186 2012 559 565
11. J. van Ingen, S.E. Totten, L.B. Heifets, M.J. Boeree, and C.L. Daley Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease Int J Antimicrob Agents 39 2012 173 176
12. M.R. Holdiness Clinical pharmacokinetics of the antituberculosis drugs Clin Pharmacokinet 9 1984 511 544
13. C.A. Peloquin Antituberculosis drugs: pharmacokinetics L. Heifets, Drug susceptibility in the chemotherapy of mycobacterial infections 1991 CRC Press Boca Raton, FL 59 88
14. S. Srivastava, J.G. Pasipanodya, C. Meek, R. Leff, and T. Gumbo Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability J Infect Dis 204 2011 1951 1959
15. J.G. Pasipanodya, S. Srivastava, and T. Gumbo Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy Clin Infect Dis 55 2012 169 177
16. C. Magis-Escurra, J. van den Boogaard, D. Ijdema, M. Boeree, and R. Aarnoutse Therapeutic drug monitoring in the treatment of tuberculosis patients Pulm Pharmacol Ther 25 2012 83 86
17. R. Ruslami, H.M. Nijland, B. Alisjahbana, I. Parwati, R. van Crevel, and R.E. Aarnoutse Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients Antimicrob Agents Chemother 51 2007 2546 2551
18. H.M. Nijland, R. Ruslami, A.J. Suroto, D.M. Burger, B. Alisjahbana, and R. van Crevel Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis Clin Infect Dis 45 2007 1001 1007
19. F. de Velde, J.W. Alffenaar, A.M. Wessels, B. Greijdanus, and D.R. Uges Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 877 2009 1771 1777
20. C.A. Peloquin Therapeutic drug monitoring in the treatment of tuberculosis Drugs 62 2002 2169 2183
21. K.A. Rodvold Clinical pharmacokinetics of clarithromycin Clin Pharmacokinet 37 1999 385 398
22. Zithromax 2005. Utrecht, The Netherlands: College ter Beoordeling van Geneesmiddelen MEB; 23 January 2006. Report No. IPD#177 10 December 1999.
23. A.D. Pranger, R. van Altena, R.E. Aarnoutse, D. van Soolingen, D.R. Uges, and J.G. Kosterink Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Eur Respir J 38 2011 888 894
24. Y. Cohen, C. Perronne, C. Truffot-Pernot, J. Grosset, J.L. Vilde, and J.J. Pocidalo Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages Antimicrob Agents Chemother 36 1992 2104 2107
25. J. Peters, W. Block, S. Oswald, J. Freyer, M. Grube, and H.K. Kroemer Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals Drug Metab Dispos 39 2011 1643 1649
26. J. van Ingen, T. van der Laan, R. Dekhuijzen, M. Boeree, and D. van Soolingen In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands Int J Antimicrob Agents 35 2010 169 173